JP2006501207A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006501207A5 JP2006501207A5 JP2004525343A JP2004525343A JP2006501207A5 JP 2006501207 A5 JP2006501207 A5 JP 2006501207A5 JP 2004525343 A JP2004525343 A JP 2004525343A JP 2004525343 A JP2004525343 A JP 2004525343A JP 2006501207 A5 JP2006501207 A5 JP 2006501207A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- crystalline form
- composition
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000003110 anti-inflammatory Effects 0.000 claims description 2
- 230000003182 bronchodilatating Effects 0.000 claims description 2
- 230000002757 inflammatory Effects 0.000 claims description 2
- 230000000414 obstructive Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N Bricaril Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 1
- BPZSYCZIITTYBL-YJYMSZOUSA-N Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 claims 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N Salbutamol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- 229960000195 Terbutaline Drugs 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 claims 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960002848 formoterol Drugs 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 229960002052 salbutamol Drugs 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 150000003839 salts Chemical group 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000012453 solvate Chemical group 0.000 claims 1
- 229940079593 drugs Drugs 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
Description
結晶形ＡまたはＢの式Ｉの化合物は、また、気道の疾患の処置のための他の医薬物質、特に気管支拡張性または抗炎症性医薬物質と共に使用するための共治療剤として、特に上記したような閉塞性または炎症性気道疾患の処置において、たとえばかかる医薬の治療効果の増強物質として、またはかかる医薬の必要とされる投薬量もしくは潜在的な副作用を減らす手段として使用される。結晶形ＡまたはＢの式Ｉの化合物は、固定された医薬組成物において他の医薬と混合され得るか、またはそれは他の医薬と別個に、他の医薬の前に、他の医薬と同時にもしくは他の医薬の後に投与され得る。
Claims (6)
- ２０℃／分の加熱速度にて、示差走査熱量測定法により２７０℃の融点（分解）を有し、Ｘ線回折図において以下の特徴的回折線（２θ（度で表記する）±０.２°）７.２°、９.３°、１２.０°、１２.８°、１３.１°、１４.５°、１７.４°、２０.４°、２３.２°および２５.８°を有する結晶形Ｂの、式Ｉ
- 所望により医薬上許容される担体とともに、活性成分として、請求項１において定義した結晶形Ｂの式Ｉの化合物の有効量を含む、炎症性または閉塞性気道疾患を処置するための医薬組成物。
- 吸入可能な形態である、請求項２に記載の組成物。
- 抗炎症性または気管支拡張性の別の医薬物質と組み合わせた請求項１において定義した式Ｉの化合物を含む医薬組成物。
- 別の医薬物質が遊離形または医薬上許容される塩もしくは溶媒和物形のサルブタモール、テルブタリン、サルメテロール、ホルモテロールおよび式
- 請求項１において定義した結晶形Ｂの式Ｉの化合物の製造方法であって、そのエタノール、メタノールまたは塩化メチレン溶液から請求項１において定義した式Ｉの化合物を結晶化させることを含む方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0217504.0A GB0217504D0 (en) | 2002-07-29 | 2002-07-29 | Organic compounds |
| GB0217504.0 | 2002-07-29 | ||
| PCT/EP2003/008314 WO2004013156A1 (en) | 2002-07-29 | 2003-07-28 | Polymorphis of a known thiophenecarboxylic acid dodecahydrocyclopenta (a) phenanthrenyl ester |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006501207A JP2006501207A (ja) | 2006-01-12 |
| JP2006501207A5 true JP2006501207A5 (ja) | 2009-05-07 |
Family
ID=9941275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004525343A Pending JP2006501207A (ja) | 2002-07-29 | 2003-07-28 | 有機化合物 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7683048B2 (ja) |
| EP (2) | EP1554303B1 (ja) |
| JP (1) | JP2006501207A (ja) |
| KR (1) | KR100688371B1 (ja) |
| CN (1) | CN1305892C (ja) |
| AR (1) | AR040692A1 (ja) |
| AT (1) | ATE349459T1 (ja) |
| AU (1) | AU2003251651B2 (ja) |
| BR (1) | BR0313044A (ja) |
| CA (1) | CA2493330C (ja) |
| CY (1) | CY1106406T1 (ja) |
| DE (1) | DE60310747T2 (ja) |
| DK (1) | DK1554303T3 (ja) |
| EC (1) | ECSP055579A (ja) |
| ES (1) | ES2279970T3 (ja) |
| GB (1) | GB0217504D0 (ja) |
| HK (1) | HK1080484B (ja) |
| IL (2) | IL166287A0 (ja) |
| MX (1) | MXPA05001173A (ja) |
| MY (1) | MY136407A (ja) |
| NO (1) | NO20050806L (ja) |
| NZ (2) | NZ549713A (ja) |
| PE (1) | PE20040722A1 (ja) |
| PL (1) | PL209409B1 (ja) |
| PT (1) | PT1554303E (ja) |
| RU (2) | RU2330043C2 (ja) |
| SI (1) | SI1554303T1 (ja) |
| TW (1) | TWI309164B (ja) |
| WO (1) | WO2004013156A1 (ja) |
| ZA (1) | ZA200500370B (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| GB0523656D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523654D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0603783D0 (en) * | 2006-02-24 | 2006-04-05 | Novartis Ag | Organic compounds |
| TWI436767B (zh) * | 2008-03-14 | 2014-05-11 | Otsuka Pharma Co Ltd | 基質金屬蛋白酶－２（ｍｍｐ－２）及／或基質金屬蛋白酶－９（ｍｍｐ－９）抑制劑 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU550939A1 (ru) * | 1975-05-19 | 1994-07-15 | Институт химии древесины АН ЛатвССР | 1,2,3,4,4а,4в,5,6,10,10а -декагидро -6- хлорацетоксиметил -1,4а-диметил -7- (1-метилэтил) -1- фенантренкарбоновая кислота или ее соли |
| JPH08291073A (ja) * | 1995-04-22 | 1996-11-05 | Kissei Pharmaceut Co Ltd | 医薬品組成物及びその製造方法 |
| GB0015876D0 (en) * | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
-
2002
- 2002-07-29 GB GBGB0217504.0A patent/GB0217504D0/en not_active Ceased
-
2003
- 2003-07-25 PE PE2003000741A patent/PE20040722A1/es not_active Application Discontinuation
- 2003-07-25 AR AR20030102680A patent/AR040692A1/es unknown
- 2003-07-28 AU AU2003251651A patent/AU2003251651B2/en not_active Ceased
- 2003-07-28 RU RU2005105688/04A patent/RU2330043C2/ru not_active IP Right Cessation
- 2003-07-28 DE DE60310747T patent/DE60310747T2/de not_active Expired - Lifetime
- 2003-07-28 CN CNB038180596A patent/CN1305892C/zh not_active Expired - Fee Related
- 2003-07-28 NZ NZ549713A patent/NZ549713A/en unknown
- 2003-07-28 CA CA2493330A patent/CA2493330C/en not_active Expired - Fee Related
- 2003-07-28 NZ NZ537868A patent/NZ537868A/en unknown
- 2003-07-28 WO PCT/EP2003/008314 patent/WO2004013156A1/en active Application Filing
- 2003-07-28 EP EP03766325A patent/EP1554303B1/en not_active Expired - Lifetime
- 2003-07-28 TW TW092120513A patent/TWI309164B/zh not_active IP Right Cessation
- 2003-07-28 MY MYPI20032832A patent/MY136407A/en unknown
- 2003-07-28 PL PL373140A patent/PL209409B1/pl not_active IP Right Cessation
- 2003-07-28 KR KR1020057001581A patent/KR100688371B1/ko not_active IP Right Cessation
- 2003-07-28 AT AT03766325T patent/ATE349459T1/de active
- 2003-07-28 SI SI200330721T patent/SI1554303T1/sl unknown
- 2003-07-28 JP JP2004525343A patent/JP2006501207A/ja active Pending
- 2003-07-28 BR BR0313044-4A patent/BR0313044A/pt not_active IP Right Cessation
- 2003-07-28 US US10/522,358 patent/US7683048B2/en not_active Expired - Fee Related
- 2003-07-28 PT PT03766325T patent/PT1554303E/pt unknown
- 2003-07-28 MX MXPA05001173A patent/MXPA05001173A/es active IP Right Grant
- 2003-07-28 ES ES03766325T patent/ES2279970T3/es not_active Expired - Lifetime
- 2003-07-28 RU RU2007143025/04A patent/RU2348646C1/ru not_active IP Right Cessation
- 2003-07-28 EP EP06005390A patent/EP1676854A1/en not_active Withdrawn
- 2003-07-28 DK DK03766325T patent/DK1554303T3/da active
-
2005
- 2005-01-13 IL IL16628705A patent/IL166287A0/xx unknown
- 2005-01-14 ZA ZA200500370A patent/ZA200500370B/en unknown
- 2005-01-26 EC EC2005005579A patent/ECSP055579A/es unknown
- 2005-02-15 NO NO20050806A patent/NO20050806L/no unknown
-
2006
- 2006-01-05 HK HK06100247.5A patent/HK1080484B/zh not_active IP Right Cessation
-
2007
- 2007-03-22 CY CY20071100400T patent/CY1106406T1/el unknown
- 2007-07-26 IL IL184848A patent/IL184848A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5466006B2 (ja) | 非常に速い皮膚浸透率を有するアセトアミノフェン及び関連化合物の正荷電水溶性プロドラッグ | |
| TWI692465B (zh) | 酚系ｔｒｐｖ１促效劑之前藥 | |
| CN104854105A (zh) | 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物 | |
| CA2781436C (en) | Arachidonic acid analogs and methods for analgesic treatment using same | |
| TW200410676A (en) | Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same | |
| JP2002517438A (ja) | 咳の治療のための組成物及び方法 | |
| US20150238456A1 (en) | Methods and compositions for administration of oxybutynin | |
| WO2018114501A1 (de) | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen | |
| US6538035B2 (en) | Use of tolterodine to treat asthma | |
| JP2024056733A (ja) | 薬剤を含む共晶溶媒、並びにその製造および使用方法 | |
| JP2009541455A5 (ja) | ||
| EP1455784A1 (en) | Analgesic delivery systems and methods of use | |
| TW202019887A (zh) | 酚系trpv1促效劑之聚乙二醇化前藥 | |
| JP2005531612A (ja) | ネフォパムの製剤および痛みの治療におけるその使用 | |
| JP2006501207A5 (ja) | ||
| JP2022508217A (ja) | Ｔａｓｋ－１およびｔａｓｋ－３チャンネル阻害剤を含有する医薬投薬形態の製造方法、ならびに呼吸障害治療におけるその使用 | |
| JP2006506402A (ja) | 四級アンモニウム化合物およびその抗ムスカリン薬としての使用 | |
| AU2013368298B2 (en) | Methods and compositions for administration of oxybutynin | |
| CN106163505B (zh) | 可吸入颗粒相关改进 | |
| JP2004231546A (ja) | 解熱鎮痛用組成物 | |
| EP3338764A1 (de) | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen | |
| JP2022120851A (ja) | グリコピロニウム・サリチル酸塩を含む医薬 | |
| EP2655328A1 (de) | Neue multikomponentenkristalle aus ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamidsäureethylester und 2-[2-[(2,6-dichlorphenyl)-amino]-phenyl]-essigsäure | |
| RU2021119540A (ru) | Глутарат 3-(1,2,3,6-тетрагидропиридин-2-ил)пиридина или его фармацевтически приемлемый сольват | |
| TW200914009A (en) | Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the preparation of a medicament for use in the treatment of cranial traumas |